Hua Medicine's 2026 interim results reveal significant year-on-year growth for HuaTangNing, with sales and revenue surging. The company is advancing its global strategy for dorzagliatin, securing new market approvals and patent term extensions, while exploring novel therapeutic combinations.
Comments